Most azole antifungal resistance mutations in the drug target provide cross-resistance and carry no intrinsic fitness cost
C. Bedard, I. Gagnon-Arsenault, J. Boisvert, S. Plante, A. K. Dube, A. Pageau, J. Sharma, L. Maroc, R. S. Shapiro, C. R. Landry
The paper evaluates 4,000 Erg11 variants to determine azole resistance and fitness costs, finding 33% resistance, 88% cross-resistance, and minimal fitness cost.
bioRxiv · Dec 13, 2023 · PreprintMicrobiology